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In this study, we show that adenoviral infection induced accumulation of the sphingolipid ceramide in a dose- and time-dependent
manner. This accumulation preceded cell lysis, occurred in the absence of biochemical evidence of apoptosis, and was derived from de novo
synthesis of ceramide. An adenovirus mutant that lacks the adenovirus death protein (ADP) produced ceramide accumulation in the absence
of cell lysis. This suggested that ceramide accumulation was either driven by adenovirus or was a cellular stress response but was unlikely a
result of cell death. The use of inhibitors of ceramide synthesis resulted in a significant delay in cell lysis, suggesting that ceramide was
necessary for the lytic phase of the infection. Serine/arginine-rich (SR) proteins were dephosphorylated during the late phase of the viral
cycle, and inhibitors of ceramide synthesis reversed this. These findings suggest that adenovirus utilizes the ceramide pathway to regulate SR
proteins during infection.
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Adenoviruses are among the most common viral infec-
tions affecting human beings of all age groups (Kojaoghla-
nian et al., 2003; Walls et al., 2003). In the past two decades,
remarkable advances in our understanding of their cycle and
their clinical importance have been made. The study of
adenoviruses has contributed to numerous discoveries that0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.09.060
Abbreviations: SR proteins, serine/arginine-rich proteins; ADP, adenovirus
death protein; Rb, retinoblastoma protein; TNFa, tumor necrosis factor a;
CAPP, ceramide-activated protein phosphatase; MOI, multiplicity of infection;
pfu, plaque-forming unit; PARP, poly(ADP)-ribose polymerase.
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E-mail address: gdbaibo@aub.edu.lb (G.S. Dbaibo).improved our understanding of viral and cellular gene
expression and regulation, DNA replication, cell cycle control,
and cellular growth regulation (Nevins, 1981, 1995). More
recently, adenoviruses are being used as novel therapeutic
tools, both as vectors of gene therapy and as oncolytic
components of multimodal cancer therapy (Doronin et al.,
2001; Nemunaitis et al., 2000; Post et al., 2003; St George,
2003).
Adenovirus contains several genes that usurp cellular
signaling pathways involved in the regulation of cellular
proliferation, death, and the immune response. These help to
ultimately insure proper propagation of the virus in the face
of a hostile cellular environment and to manipulate the host
machinery in the interest of viral replication. Some
adenoviral proteins, such as E1A and E4 gene products,
promote host cell proliferation by driving an otherwise
stationary or slow cell cycle, thus providing an optimal6) 280 – 289
www.e
Fig. 1. Effect of adenovirus infection on ceramide levels and cell lysis. (A)
Dose-dependent increase in ceramide and cell lysis. MCF7 cells were infected
with rec700 adenovirus at the indicated MOIs. Cells were harvested at 48
h post-infection, and ceramide was measured as described in Materials and
methods. Cell lysis was determined using the trypan blue exclusion assay. (B)
Time-dependent increase in ceramide and cell lysis. MCF7 cells were infected
with adenovirus rec700 as in panel A at an MOI of 160 pfu/cell and harvested
at the indicated time points. Ceramide levels and cell lysis were measured as in
panel A. Data are representative of at least three independent experiments.
S.S. Kanj et al. / Virology 345 (2006) 280–289 281environment for viral replication (Leppard, 1997; Nevins,
1995). In the case of E1A, this is accomplished by targeting
key cellular proteins that control cell cycle such as the
retinoblastoma protein (Rb) (Dyson et al., 1989; Mal et al.,
1996; Whyte et al., 1989). Other adenoviral genes, such as
E1B19K, E1B55K, and most of the E3 genes, encode for
proteins whose function is to help the virus evade the innate
immune response and to prevent early apoptosis by
inhibiting the tumor suppressor p53 and other apoptotic
pathways, thus delaying the elimination of infected cells
long enough until sufficient viral progeny is produced
(Gooding, 1992; Han et al., 1998; Perez and White, 1998;
Wold et al., 1999).
Among the emerging regulators of cell proliferation and
apoptosis is ceramide, a putative coordinator of the cellular
stress response by virtue of its ability to induce cell cycle
arrest by regulating Rb and to induce p53-independent
apoptosis (Dbaibo et al., 1995; Jayadev et al., 1995; Obeid
et al., 1993). Thus, ceramide shares functional properties
with some targets of adenoviral genes, namely, Rb and p53.
However, the targeting of ceramide pathways by adenovirus
has not been examined.
The cellular levels of ceramide are regulated by the
balance of the rates of its de novo synthesis that begins with
the condensation of serine and palmitoyl-CoA, its hydrolysis
to sphingosine and fatty acid, its incorporation into more
complex sphingolipids, and its generation from the hydroly-
sis of these compounds (Hannun and Obeid, 2002). Inducers
of ceramide accumulation include tumor necrosis factor a
(TNFa), Fas ligation, serum deprivation, heat shock, and
ionizing irradiation (Chang et al., 1995; Haimovitz-Friedman
et al., 1994; Jayadev et al., 1995; Kim et al., 1991; Tepper
et al., 1995). After stimulation with one of the inducers,
ceramide levels begin to increase over a period of minutes or
hours, and, depending on the cell type and inducer, cells
undergo differentiation, cell cycle arrest, senescence, or
apoptosis. Downstream effector targets of ceramide include
ceramide-activated phosphatases (CAPP) and, less directly,
several ceramide-activated kinases (Dobrowsky and Hannun,
1992; Liu et al., 1994; Zhang et al., 1997). The first CAPP
identified is a member of the 2A family of serine/threonine
protein phosphatases and was shown to be an effector
molecule for ceramide-induced biology (Wolff et al., 1994).
PP2A was found in yeast Saccharomyces cerevisiae to
mediate ceramide-induced growth arrest (Fishbein et al.,
1993). Another more recently identified CAPP is PP1 that
was shown to be potently stimulated by naturally occurring
ceramides and to mediate ceramide-induced caspase activa-
tion (Chalfant et al., 1999; Kishikawa et al., 1999). Among
the PP1 substrates that were identified, serine/arginine-rich
(SR) proteins emerged as the most relevant to the apoptotic
functions of ceramide. These proteins are regulated by
phosphorylation and play an important role in alternative
splicing of several apoptosis regulatory genes in response to
external death stimuli (Chalfant et al., 2001). In this study,
we examine the effects of adenoviral infection on ceramide
pathways and the role it plays during infection.Results
Adenovirus infection induces ceramide accumulation
The effects of adenovirus infection on the ceramide
response were examined. Infection of MCF7 cells with
increasing multiplicity of infection (MOI) of adenovirus
rec700 (wild type) was done (Fig. 1A). At 48 h, cells were
harvested, and ceramide levels were measured and compared to
time-matched controls. It was found that ceramide levels
increased with increasing MOI, reaching a plateau of about
4-fold of baseline levels at an MOI of 80 pfu/cell. The time
course of ceramide increase following infection was then
examined (Fig. 1B). Infection with rec700 at 160 pfu/cell
resulted in a gradual increase in ceramide starting at 24 h and
increasing steadily with time to reach 4-fold of baseline levels
by 48 h. When lower MOIs were examined, we found that, at
an MOI of 20 pfu/cell, ceramide levels started to increase at 48
Fig. 2. Lack of PARP cleavage during adenovirus infection. MCF7 cells were
either mock-infected (ve Control) or infected for 48 h with rec700 adenovirus
at an MOI of 250 pfu/cell or 500 pfu/cell. Total protein lysates (100 Ag) were
subjected to 10% SDS-PAGE analysis and immunoblotted for PARP protein.
Positive control for PARP cleavage was used consisting of lysates from MCF7
cells treated with TNFa for 24 h. The cleaved ‘‘apoptotic’’ fragment is indicated
at 89 kDa.
Fig. 3. Ceramide accumulates in the absence of cell lysis after infection with an
E3 mutant adenovirus. MCF7 cells were infected with adenovirus dl7001 that
lacks all the E3 genes at an MOI of 500 pfu/cell. Ceramide levels and cell lysis
were determined as in Fig. 1B.
S.S. Kanj et al. / Virology 345 (2006) 280–289282h and reached 3-fold of baseline levels by 96 h (data not
shown). Similar results were obtained when A549 lung
adenocarcinoma cells were used (data not shown). These
findings suggested that adenoviral infection was associated
with a significant accumulation of ceramide.
Relationship of accumulated ceramide with
adenovirus-induced cell death
Due to the demonstrated association between ceramide
accumulation and various forms of cell death including
apoptosis, we investigated the relationship of ceramide and
cell death during adenoviral infection. In human cells,
adenovirus induces a lytic infection where mature virions
are released from the infected cell at the end of the viral
replication cycle. In order to determine whether cell lysis
occurred before, with, or after ceramide accumulation,
MCF7 cells were infected with rec700 adenovirus at several
doses and were analyzed for cell death using the trypan blue
exclusion assay at 48 h post-infection and compared to
mock-infected controls. At the lower doses, adenovirus
caused no cell death at 48 h, although significant ceramide
accumulation had occurred with these doses (Fig. 1A). The
time course of cell death following adenoviral infection was
examined next. Infection of MCF7 cells with rec700 at 160
pfu/cell was performed and cell death determined at the
indicated time points. There was no significant death in
MCF7 cells by 24 h post-infection as compared to controls.
By 36 h post-infection, about 10% of the cells were dead,
and cell death continued to rise in a time-dependent manner,
reaching 30% by 48 h post-infection (Fig. 1B). These
findings indicated that ceramide accumulation occurred prior
to cell lysis during adenoviral infection in a closely related
manner.
In several systems, ceramide has been shown to induce
apoptosis. Therefore, we examined whether, during adeno-
viral infection, ceramide played a role in the regulation of
viral-induced apoptosis. Adenovirus encodes for several
anti-apoptotic proteins such as E1B 19K and E1B 55K
that function to prevent or delay apoptosis in order for the
viral replication cycle to be completed. Therefore, apoptosis
following infection of MCF7 cells with rec700 adenovirus
was examined by assaying for poly(ADP)-ribose polymerase
(PARP) cleavage from its native 116 kDa to an ‘‘apoptotic’’
fragment of 89 kDa by the specific action of caspases.Infection with rec700 at an MOI of 250 or 500 pfu/cell
resulted in cell death as measured by trypan blue uptake of
46% and 64%, respectively. This occurred in the absence of
significant PARP cleavage, suggesting that non-apoptotic
cell death was induced during adenoviral infection (Fig. 2).
In comparison, treatment of MCF7 cells with 3 nM TNFa
for 24 h resulted in cell death of 65% and significant
PARP cleavage. Therefore, ceramide accumulation during
adenoviral infection was accompanied by non-apoptotic cell
death.
Ceramide accumulates in the absence of cell lysis
Since ceramide accumulation was accompanied by cell
lysis that lacked biochemical features of apoptosis, it was
important to verify that ceramide accumulation was not
caused by nonspecific activation of biochemical pathways
that generate ceramide during cell lysis. Thus, a mutant
adenovirus dl7001 that lacks the E3 gene cassette was
utilized. This virus lacks the E3 11.6 K adenovirus death
protein (ADP) that is essential for cell lysis and viral release.
Cell death in MCF7 cells infected with 500 pfu/cell of
dl7001 was determined using the trypan blue exclusion
assay. Infection induced only 7% death in the MCF7 cells as
compared to 5% of mock-infected control cells at 36 h post-
infection with no significant rise at later time points (Fig. 3).
However, when ceramide levels were measured in the MCF7
cells infected with the mutant virus, they were found to have
significantly increased levels, comparable to those achieved
with wild type virus infection (Fig. 3). Similar results were
obtained when A549 cells or when lower MOIs and longer
time points were used (data not shown). These findings lead
to two conclusions relating to ceramide accumulation during
adenoviral infection: 1) ceramide did not accumulate due to
nonspecific activation of relevant biochemical pathways
during cell lysis, and 2) ceramide accumulation did not
necessarily result in cell death.
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Several biochemical pathways are involved in regulating
cellular ceramide levels. Activation of sphingomyelinases
results in the hydrolysis of membrane sphingomyelin and
generation of ceramide. Inhibition of enzymes that metabolize
ceramide such as ceramidases and glucosylceramide synthase
also results in the accumulation of cellular ceramide.
Alternatively, ceramide can be generated by de novo synthesis
from the condensation of serine and palmitate. Several stimuli
were demonstrated to activate one or more of these pathways
in many cell types. In MCF7 cells, TNFa was shown to
activate magnesium-dependent neutral sphingomyelinase to
generate a modest increase in ceramide at early time points
and to activate de novo synthesis to generate more elevated
and sustained levels of ceramide at later time points (Dbaibo
et al., 2001). Adenoviral infection of MCF7 cells induced late
accumulation of ceramide. This raised the possibility that the
de novo synthesis pathway was involved. In order to examine
this possibility, we used the ceramide synthase inhibitor
Fumonisin B1. When MCF7 cells were treated with Fumo-
nisin B1 [100 AM] at the time of infection with the wild typeFig. 4. Ceramide accumulates by de novo synthesis during adenoviral infection. (A)
adenoviral infection. MCF7 cells were treated with Fumonisin B1 100 AM (FB1) or M
harvested at 24, 36, and 48 h post-infection, and ceramide was measured. (B and C
adenoviral infection. MCF7 cells were pulse labeled with 1 ACi/ml [3H]-palmitate
Fumonisin B1 or Myriocin. Cells were harvested at the indicated time points. Lipids
following base hydrolysis as described in Materials and methods. The TLC from
ceramide is shown in panel C.adenovirus rec700, the increase in ceramide between 24 and
48 h post-infection was completely inhibited as compared to
time-matched controls (Fig. 4A). Similar results were
obtained when the serine–palmitoyl transferase inhibitor
Myriocin was used (Fig. 4A). This suggested that ceramide
accumulation in response to adenoviral infection was mainly
derived from the de novo synthesis pathway.
To directly assess the role of the de novo ceramide
biosynthesis in cells in response to adenoviral infection,
MCF7 cells were labeled with [3H]-palmitate and then
infected with wild type adenovirus with and without co-
treatment with Fumonisin B1 or Myriocin. An increase in
the incorporation of palmitate into ceramide upon wild type
adenoviral infection was found, starting as early as 24 h and
sustained at 48 h post-infection, as compared to controls. As
expected, treatment with Fumonisin B1 or Myriocin
completely abrogated the incorporation of palmitate into
the complex sphingolipids including ceramide (Figs. 4B and
C). Comparable results were obtained when we radiolabeled
A549 cells (data not shown). These studies supported a
major role for de novo synthesis of ceramide as a source of
accumulated ceramide during adenoviral infection.Inhibitors of de novo ceramide synthesis block ceramide accumulation during
yriocin 50 nM at the time of infection with rec700 adenovirus (Ad). Cells were
) Evidence of de novo synthesis of ceramide by [3H]-palmitate labeling during
at the time of infection with rec700 adenovirus in the presence or absence of
were extracted, and the newly synthesized ceramide band was separated on TLC
the 36-h time point is shown in panel B. Quantitation of newly synthesized
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infected cells
Ceramide has been implicated in the regulation of apoptosis
as well as necrosis. Whereas lysis of adenovirus-infected cells
lacks biochemical or morphological features of apoptosis, there
is evidence that it is a regulated process that is dependent, at
least in part, on viral ADP (Tollefson et al., 1996). In order to
determine whether ceramide plays a role in lysis of infected
cells, we utilized the inhibitors of de novo ceramide synthesis
Fumonisin B1 and Myriocin. Infection of MCF7 cells was
performed in the presence of either of the ceramide synthesis
inhibitors, and cells were evaluated at 24, 36, and 48 h by
phase contrast microscopy (Fig. 5A) and by uptake of trypan
blue (Fig. 5B). It was found that both inhibitors were capable
of significantly delaying cell lysis as reflected by cell rounding,
detachment, and loss of membrane integrity. These studiesFig. 5. Inhibition of ceramide synthesis delays cell lysis during adenoviral infection.
cell as in Fig. 1 in the presence or absence of Fumonisin B1 100 AM (FB1) or Myrio
Phase contrast microscopy. (B) Determination of cell lysis by trypan blue exclusiosuggested that the accumulation of ceramide was a necessary
step in cell lysis during infection.
Adenovirus-induced dephosphorylation of SR proteins is
regulated by de novo synthesized ceramide
During adenoviral infection, lysis of infected cells occurs
after completion of viral replication and is dependent on ADP
for efficient release of virions. During the late stages of viral
replication cycle, alternative splicing of the L1 gene results in
the shift from the 52,55 K mRNA produced early in the
infectious cycle to the IIIa mRNA that is predominant in the
late stages of the cycle (Kanopka et al., 1996). This process is
regulated by cellular spliceosomes that process pre-mRNA into
mature mRNA. SR proteins are important components of
spliceosomes. A subset of SR proteins is specifically targeted
by adenovirus via its E4orf4 splicing enhancer protein, whichMCF7 cells were infected with rec700 adenovirus (Ad) at an MOI of 160 pfu/
cin 50 nM at the time of infection and evaluated at the indicated time points. (A)
n.
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dephosphorylation of SR proteins (Estmer Nilsson et al., 2001;
Kanopka et al., 1998; Marcellus et al., 2000). Ceramide
generated by the de novo synthesis pathway was recently
implicated in the regulation of SR proteins by virtue of its
activation of protein phosphatase 1 (PP1), which also targets
SR proteins as substrates (Chalfant et al., 2001, 2002).
Therefore, we examined whether ceramide generated by de
novo synthesis during adenoviral infection was involved in SR
protein regulation. Using an antibody that recognizes aFig. 6. Adenovirus-induced ceramide regulates the phosphorylation state of SR
proteins. (A) Myriocin inhibits adenoviral-induced dephosphorylation of SR
proteins. A549 cells were infected with rec700 adenovirus (Ad) in the presence
or absence of Myriocin 50 nM, and total protein lysates were prepared at the
indicated time points and subjected to Western blotting using the SR phospho-
specific antibody mAb104. Phosphorylated SR proteins are indicated with
closed arrows. (B and C) Fumonisin B1 inhibits adenoviral-induced dephos-
phorylation of SR proteins in A549 (B) and MCF7 (C) cells. A549 (B) or
MCF7 (C) cells were infected with rec700 adenovirus in the presence or
absence of Fumonisin B1 100 AM, and total protein lysates were prepared at the
indicated time points. Immunoblotting for phosphorylated SR proteins
(mAb104), for total SRp30 (ASF/SF2), or for total SRp20 was performed.
Total SR proteins are indicated.phosphoepitope common to all SR proteins, it was found that
a subset of SR proteins that includes SR p75, SR p55, SR p40,
SR p30, and SR p20 was dephosphorylated in adenoviral-
infected MCF7 or A549 cells, a response detected at 48 and 72
h post-infection coinciding with the significant rise in ceramide
accumulation during infection (Fig. 6). When cells were treated
with Myriocin at the time of infection, dephosphorylation was
significantly inhibited (Fig. 6A). Similar results were obtained
when Fumonisin B1 was used in A549 (Fig. 6B) or MCF7
(Fig. 6C) cells. These data indicated that the induction of de
novo ceramide synthesis during adenoviral infection plays a
significant role in the dephosphorylation of SR proteins.
Discussion
In this study, we demonstrate that ceramide levels increase
in response to adenoviral infection in at least two different cell
types. This increase starts several hours after the expression of
early viral genes such as E1A (data not shown) and precedes
any evidence of cell lysis. Moreover, the increase in ceramide
occurs in the absence of cell lysis as shown in Fig. 3 following
infection with dl7001 that lacks all E3 genes including ADP.
These findings indicate that ceramide accumulation during
adenoviral infection is not a result of cell lysis with nonspecific
activation of ceramide-generating pathways nor is it due to the
expression of ADP. In addition, the accumulated ceramide is
generated mostly by de novo synthesis. The fact that an
infected and dying cell is spending valuable energy to actively
synthesize ceramide suggests an important role that ceramide
plays during adenoviral infection.
In other systems, such as the treatment of MCF7 cells with
TNFa or the treatment of A549 cells with chemotherapeutic
agents, ceramide elevation was followed shortly by apoptosis
with typical morphological and biochemical features (Dbaibo
et al., 1997; Ogretmen et al., 2001). However, in the current
study, it was found that infection with wild type adenovirus
resulted in ceramide elevation that was followed by non-
apoptotic cell lysis. The lack of apoptosis was most likely due
to the expression of the E1B19K gene product. E1B19K is a
viral homolog of the cellular anti-apoptotic protein Bcl-2 and
shares its ability to inhibit apoptosis (Chiou et al., 1994). This
is accomplished by binding to several of the pro-apoptotic
members of the Bcl-2 family including Bax and Bak and
inhibiting the mitochondrial release of cytochrome C (Han et
al., 1998; Perez and White, 1998). Bcl-2 was shown, in several
systems, to function ‘‘downstream’’ of ceramide. For example,
MCF7 cells that overexpress Bcl-2 were not only resistant to
apoptosis induced by TNFa but were also resistant to
ceramide-induced apoptosis (Dbaibo et al., 1997; El-Assaad
et al., 1998). In response to TNFa, these cells accumulated
significant levels of ceramide without undergoing apoptosis.
Thus, it is reasonable to speculate that the expression of
E1B19K during adenoviral infection may act downstream of
ceramide to block ceramide-induced apoptosis.
Two lines of evidence from this study strongly suggest that
the bulk of the accumulated ceramide was produced from the
de novo biosynthetic pathway. First, the activities of ceramide
S.S. Kanj et al. / Virology 345 (2006) 280–289286synthase and serine–palmitoyl transferase were required for
ceramide accumulation. Inhibition of either enzyme by
Fumonisin B1 or Myriocin, respectively, resulted in significant
attenuation of ceramide increase (Desai et al., 2002; Perry,
2000). Second, adenoviral infection caused active de novo
ceramide production as demonstrated by palmitate labeling
studies. The fact that either Fumonisin B1 or Myriocin was
capable to significantly delay cell rounding, detachment, and
lysis as compared to wild type infected cells suggests that
ceramide generated by the de novo pathway is required for
completion of the infectious cycle and lysis of the infected
cells. A limitation of these experiments though is that treatment
with Fumonisin B1 or Myriocin for prolonged periods, in
addition to preventing ceramide synthesis, results in the
depletion of sphingolipids derived from ceramide. Thus,
depletion of more complex sphingolipids might contribute to
the delayed lysis observed after Fumonisin B1 or Myriocin
treatment.
The lack of apoptosis after ceramide accumulation
combined with the delay in cell lysis after adenoviral
infection when ceramide synthesis was inhibited raised
questions regarding the role of ceramide accumulation
during adenoviral infection. Was ceramide increased simply
as a ‘‘stress response’’ to viral infection? In this regard, was
ceramide one of the cellular weapons to counteract the
effects of adenoviral genes to promote cell proliferation and
prevent apoptosis? Alternatively, was ceramide elevation
driven by adenovirus in order to accomplish specific effects
that are necessary for completion of the adenoviral lytic
cycle? Previously, de novo synthesized ceramide was shown
to regulate SR protein function, and this raised the
possibility that ceramide may regulate alternative splicing
during adenoviral infection.
SR proteins are serine/arginine-rich proteins that constitute
a family of pre-mRNA splicing factors (Manley and Tacke,
1996). They are involved in multiple steps of the constitutive
splicing reaction by insuring the correct assembly of a
functional spliceosome and are important regulators of
alternative splicing where they can function either positively
or negatively to enhance or repress the utilization of specific
splice sites (Furuyama and Bruzik, 2002; Hastings and
Krainer, 2001; Lynch and Maniatis, 1995; Smith and
Valcarcel, 2000; Tacke and Manley, 1999; Tian and Maniatis,
1992). SR proteins exist in the cell as phosphoproteins where
reversible phosphorylation significantly regulates their func-
tion (Colwill et al., 1996; Gui et al., 1994; Mermoud et al.,
1994). De novo ceramide accumulation in response to Fas
activation and heat shock was shown to induce dephosphor-
ylation of SR proteins by activation of protein phosphatase 1
(Chalfant et al., 2001). In the context of Fas treatment, this
resulted in alternative splicing of two key apoptotic genes,
caspase 9 and Bcl-x. In both cases, ceramide treatment
favored the production of the alternatively spliced pro-
apoptotic transcripts caspase-9L and Bcl-xs (Chalfant et al.,
2002). Similarly, alternative splicing by SR proteins was
essential during lytic adenoviral infection where SR proteins
were involved in the alternative splicing of the adenoviral lateL1 gene. Transcription of the gene produces a precursor
mRNA that can be alternatively spliced to produce either the
52/55K or the IIIa mRNAs. This is temporally regulated in
such a way that the efficient use of the IIIa splice site is
confined to the late phase of the cycle (Estmer Nilsson et al.,
2001; Molin and Aku¨sjarvi, 2000). Indeed, the E4orf4
adenoviral gene product was shown to associate with PP2A,
forming a complex that was able to induce dephosphorylation
of SR proteins and hence regulate the temporal shift in
adenovirus alternative RNA splicing (Estmer Nilsson et al.,
2001; Kanopka et al., 1998). Thus, the findings from the
current study that ceramide was necessary for dephosphory-
lation of SR proteins during adenoviral infection suggest that,
in addition to the E4orf4/PP2A pathway, adenovirus may
utilize the ceramide/PP1 pathway to regulate SR protein
function.
Our findings begin to define a role for ceramide during
adenoviral infection and raise the possibility that adenovirus
might hijack the ceramide pathway in order to promote




MCF7 M1 breast carcinoma epithelial cells were previously
obtained from Vishva Dixit, University of Michigan, Ann
Arbor, A549 lung carcinoma cells were a kind gift from Besim
Ogretmen Medical University of South Carolina, Charleston.
Adenovirus rec700 (recombinant of adenovirus types 2 and 5)
and E3 dl7001 (deleted in all of the E3 transcription unit)
were described previously (Gooding et al., 1991). Myriocin
was from Sigma. Fumonisin B1 was from Alexis. ENHANCE
was from Perkin-Elmer Life Sciences. [g-32P]-ATP and
[9,10-3H(N)]-palmitate were from Amersham Biosciences.
mAb104 (phospho-SR protein antibody) hybridoma cells were
purchased from ATCC. ASF/SF2 (SRp30) and SRp20 anti-
bodies were from Santa Cruz.
Cell culture
MCF7 M1, breast carcinoma epithelial cells, and A549 lung
carcinoma epithelial cells were maintained in RPMI 1640 and
DMEM (GIBCO), respectively, containing 10% fetal bovine
serum (GIBCO) at 37 -C in 5% CO2. For experimental studies,
cells were prepared by seeding 3  105 cells in 6 ml of medium
containing 10% fetal bovine serum and resting them overnight
before infection. Infection studies were performed using serum-
free medium for 75 min, and then volume was completed to
10% fetal bovine serum.
Growth studies
Cells were harvested at the indicated time points from
cultures, and aliquots were diluted with equal volumes of
trypan blue solution. Both trypan blue negative and positive
S.S. Kanj et al. / Virology 345 (2006) 280–289 287cells were counted, and the percentage of dead cells was
determined.
Ceramide measurements
Lipids were collected according to the method of Bligh
and Dyer. Ceramide was measured with a modified diacyl-
glycerol kinase assay using external ceramide standards as
described. Briefly, 80% of the lipid sample was dried under
N2. The dried lipid was solubilized in 20 Al of an octyl-h-d-
glucoside/dioleoyl phosphatidylglycerol micellar solution
(7.5% octyl-h-d-glucoside, 25 mM dioleoyl phosphatidylgly-
cerol) by several cycles of sonication in a bath sonicator
followed by resting at room temperature for 15–20 min. The
reaction buffer was prepared as a 2 solution, containing 100
mM imidazole HCL, pH 6.6, 100 mM LiCl, 25 mM MgCl2,
and 2 mM EGTA. To the lipid micelles, 50 Al of 2 reaction
buffer was added, 0.2 Al of 1 M dithiothreitol, 5 Ag of
diglycerol kinase membranes, and dilution buffer (10 mM
imidazole, pH 6.6, 1 mM diethylenetriaminepentaacetic acid,
pH 7) to a final volume of 90 Al. The reaction was started by
adding 10 Al 2.5 mM [g-32P]ATP solution (specific activity of
75,000–200,000 cpm/nmol). The reaction was allowed to
proceed at 25 -C for 30 min. Bligh and Dyer (1959) lipid
extraction was done, and a 1.5 ml aliquot of the organic phase
was dried under N2. Lipids were then resuspended in a
volume of 50 Al methanol:chloroform (1:9, v/v), and 25
Al was spotted on a 20 cm silica gel thin layer chromatog-
raphy plate. Plates were developed with chloroform:acetone:
methanol:acetic acid:H2O (50:20:15:10:5), air dried, and
subjected to autoradiography. The radioactive spots
corresponding to phosphatidic acid and ceramide–phosphate,
the phosphorylated products of diacylglycerol and ceramide,
respectively, were identified by comparison to known
standards. Spots were scraped into a scintillation vial
containing 4 ml of scintillation fluid and counted on a
scintillation counter. Linear curves of phosphorylation were
produced over a concentration range of 0–960 pM of external
standards (dioleoyl glycerol and CIII ceramide; Sigma).
Ceramide levels were always normalized to lipid phosphate,
which was measured according to the method of Rouser et al.
(1970). It is important to note that, under these conditions,
there was total conversion of ceramide and diacylglycerol to
their phosphorylated products, and there was no change in the
specific activity of the diacylglycerol kinase enzyme.
For assessing de novo ceramide synthesis, labeling with
palmitate was utilized. Cells were seeded at 3  105 cells/well
in 6-well culture plates in RPMI with 10% FBS (3.5 ml of
media/well). Cells were allowed to grow for 24 h and then were
infected in serum-free RPMI medium for 75 min in the
presence of 5 ACi/well of [9,10-3H(N)]-palmitate after which
the volume was completed to provide a final concentration of
10% FBS. At 18, 24, and 48 h, cells were harvested, washed
once in ice-cold PBS, and lipids extracted according to Bligh
and Dyer. One third of lipid extract was used for lipid
phosphate determination. The other two thirds were base-
hydrolyzed and the resulting lipids resolved on TLC (solventsystem of chloroform:methanol:2 N NH4OH; 40:10:1). Plates
were dried, sprayed with ENHANCE, and exposed to film and
3H-lipids were identified. The lipid co-migrating with a
ceramide standard was scraped from the TLC plate and
quantified by liquid scintillation spectroscopy. Results are
expressed as cpm of ceramide/nmol lipid-Pi.
Western blotting
Cells were harvested by centrifugation at 1500 rpm for 10
min and washed in ice-cold PBS. Proteins were extracted by
direct lysis with sample buffer and were separated on a 10%
and 12% SDS-PAGE gels for PARP and SR proteins,
respectively and then transferred to a nitrocellulose membrane.
Blots were blocked with 5% milk in PBS containing 0.3%
Tween 20 and then incubated with the corresponding primary
antibody, 1:1000 for PARP, 1:25 for mAb104, and 1:100 for
ASF/SF2 and SRp20 antibodies. Bands were developed using
the enhanced chemiluminescence detection system (ECL,
Amersham Biosciences).
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